New developments in sentinel node staging in melanoma: controversies and alternatives
Alexander C J van Akkooi1, Christiane A Voit, Cornelis Verhoef
1Department of Surgical Oncology, Erasmus University Medical Center - Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Current Opinion in Oncology
|February 20, 2010
Summary
Sentinel lymph node biopsy is crucial for melanoma prognosis, but its accuracy and therapeutic benefit require further study. Minimal tumor burden in sentinel nodes offers prognostic value, with ultrasound emerging as a cost-effective alternative.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Melanoma incidence is rising globally.
- Elective lymph node dissections do not improve survival.
- Sentinel lymph node biopsy targets occult metastases.
Purpose of the Study:
- Analyze controversies surrounding sentinel lymph node biopsy in melanoma.
- Evaluate false-negative rates and therapeutic benefits.
- Assess the clinical relevance of minimal sentinel node tumor burden.
Main Methods:
- Review of current literature and clinical trial data.
- Analysis of prognostic factors in melanoma.
- Evaluation of emerging diagnostic techniques.
Main Results:
- Sentinel lymph node status is an independent prognostic factor for melanoma survival.
- False-negative rates are often underestimated.
- Subgroup analyses suggest potential survival benefits, but require further validation.
Conclusions:
- Sentinel lymph node tumor burden provides prognostic information.
- Ongoing studies (MSLT-2, MINITUB) address optimal patient selection for completion lymph node dissection.
- Rotterdam criteria offer reproducible measurement of tumor burden; ultrasound-guided fine needle aspiration cytology is a promising alternative.
